Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Good morning. I was extremely confused when I saw a Spirit Halloween pop-up yesterday, but then realized October is indeed next month. Very spooky.

The need-to-know this morning

• UniQure submitted applications to the FDA and the UK’s MHRA, seeking the marketing approval of AMT-130, its treatment for Huntington’s disease.

New Trump deals may undercut efforts to lower costs 

The midterms are fast approaching, and President Trump hailed the new deals he struck with biopharma companies this week as part of his commitment to lowering drug costs. But in reality, the agreements may not amount to much, STAT’s John Wilkerson writes — and could even undercut the administration’s own efforts.

Continue to STAT+ to read the full story…